Literature DB >> 7936086

Trans retinoic acid inhibits in vivo tumour growth of C6 glioma in rats: effect negatively influenced by nerve growth factor.

G E Rodts1, K L Black.   

Abstract

Retinoic acid (RA) and nerve growth factor (NGF) are both differentiation factors for central nervous system tumours. Mouse-derived NGF inhibits proliferation of C6 glioma cells in vivo in the absence of serum. Retinoic acid inhibits in vivo growth of C6 gliomas in the subcutaneous tissue of rats. This study evaluated the response of C6 cells implanted in the rat cortex to NGF, RA, or a combination of the two in 89 rats. Tumour size, cellular density and morphology were analysed using light microscopy. Treatment with RA alone resulted in tumour volumes that were 38% of control and 48% of NGF-treated groups. There was no significant difference in the tumour volumes or in cell morphology in C6 cells treated with NGF alone compared to controls. Tumours treated with a combination of RA and NGF were larger however, than tumours treated with RA alone. This suggests that despite the growth inhibitory effects of NGF in vitro, NGF acts to prevent the growth inhibitory effect of RA in vivo.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7936086     DOI: 10.1080/01616412.1994.11740223

Source DB:  PubMed          Journal:  Neurol Res        ISSN: 0161-6412            Impact factor:   2.448


  11 in total

1.  Paucity of retinoic acid receptor alpha (RAR alpha) nuclear immunostaining in gliomas and inability of retinoic acid to influence neural cell adhesion molecule (NCAM) expression.

Authors:  B K Kleinschmidt-DeMasters; E A Orr; E Savelieva; G C Owens; C A Kruse
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

2.  Radiotherapy and temozolomide for anaplastic astrocytic gliomas.

Authors:  Lakshmi Nayak; Katherine S Panageas; Anne S Reiner; Jason T Huse; Elena Pentsova; Stephanie G Braunthal; Lauren E Abrey; Lisa M DeAngelis; Andrew B Lassman
Journal:  J Neurooncol       Date:  2015-04-29       Impact factor: 4.130

3.  The treatment of recurrent cerebral gliomas with all-trans-retinoic acid (tretinoin).

Authors:  S E Kaba; A P Kyritsis; C Conrad; M J Gleason; R Newman; V A Levin; W K Yung
Journal:  J Neurooncol       Date:  1997-09       Impact factor: 4.130

4.  Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitors.

Authors:  Israel S Fernández; Pedro Cuevas; Javier Angulo; Pilar López-Navajas; Angeles Canales-Mayordomo; Rocío González-Corrochano; Rosa M Lozano; Serafín Valverde; Jesús Jiménez-Barbero; Antonio Romero; Guillermo Giménez-Gallego
Journal:  J Biol Chem       Date:  2010-02-09       Impact factor: 5.157

5.  Resolution of recurrent malignant ganglioglioma after treatment with cis-retinoic acid.

Authors:  S E Kaba; L A Langford; W K Yung; A P Kyritsis
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

6.  Nerve growth factor plays a divergent role in mediating growth of rat C6 glioma cells via binding to the p75 neurotrophin receptor.

Authors:  Carla Weis; Bettina Wiesenhofer; Christian Humpel
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

7.  ATRA-inhibited proliferation in glioma cells is associated with subcellular redistribution of beta-catenin via up-regulation of Axin.

Authors:  Jianrong Lu; Feng Zhang; Daqing Zhao; Liu Hong; Jie Min; Liying Zhang; Fanfan Li; Yan Yan; Hang Li; Yu Ma; Qing Li
Journal:  J Neurooncol       Date:  2008-01-23       Impact factor: 4.130

8.  Maintenance therapy with 13-cis retinoid acid in high-grade glioma at complete response after first-line multimodal therapy--a phase-II study.

Authors:  Caecilia Wismeth; Peter Hau; Klaus Fabel; Ulrike Baumgart; Birgit Hirschmann; Horst Koch; Tanja Jauch; Oliver Grauer; Lisa Drechsel; Alexander Brawanski; Ulrich Bogdahn; Andreas Steinbrecher
Journal:  J Neurooncol       Date:  2004-05       Impact factor: 4.130

9.  Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.

Authors:  Jennifer L Clarke; Fabio M Iwamoto; Joohee Sul; Katherine Panageas; Andrew B Lassman; Lisa M DeAngelis; Adília Hormigo; Craig P Nolan; Igor Gavrilovic; Sasan Karimi; Lauren E Abrey
Journal:  J Clin Oncol       Date:  2009-06-08       Impact factor: 44.544

10.  Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma.

Authors:  M W Pitz; M Lipson; B Hosseini; P Lambert; K Guilbert; D Lister; G Schroeder; K Jones; C Mihalicioiu; D D Eisenstat
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.